# reload+after+2024-01-22 00:46:06.169956
address1§One Cavendish Place
address2§4th Floor
city§London
zip§W1G 0QF
country§United Kingdom
phone§44 33 3023 7300
website§https://www.mereobiopharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
fullTimeEmployees§36
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Denise  Scots-Knight Ph.D.', 'age': 64, 'title': 'Co-Founder, CEO & Executive Director', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 885560, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Charles  Sermon', 'age': 54, 'title': 'Co-Founder, General Counsel & Company Secretary', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. John P. Richard M.B.A.', 'age': 66, 'title': 'Co-Founder & Chief Business Officer', 'yearBorn': 1957, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Christine  Fox CPA', 'age': 42, 'title': 'Chief Financial Officer', 'yearBorn': 1981, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. John A. Lewicki Ph.D.', 'age': 71, 'title': 'Chief Scientific Officer', 'yearBorn': 1952, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jackie  Parkin', 'age': 65, 'title': 'Senior VP & Therapeutic Head', 'yearBorn': 1958, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Alexandra  Hughes-Wilson', 'age': 52, 'title': 'Chief of Patient Access & Commercial Planning', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Suba  Krishnan', 'age': 58, 'title': 'Senior Vice President of Clinical Development', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Bo  Kara', 'title': 'Senior VP and Head of Pharmaceutical Development & CMC', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.802
priceToSalesTrailing12Months§48.400364
currency§USD
dateShortInterest§1702598400
forwardEps§-52.0
exchange§NCM
quoteType§EQUITY
shortName§Mereo BioPharma Group plc
longName§Mereo BioPharma Group plc
firstTradeDateEpochUtc§1556112600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§2bb59234-2dd4-3418-a5f3-ada28f11788c
gmtOffSetMilliseconds§-18000000
targetHighPrice§5.02
targetLowPrice§4.02
targetMeanPrice§4.27
targetMedianPrice§4.02
recommendationMean§1.5
recommendationKey§strong_buy
numberOfAnalystOpinions§4
quickRatio§3.027
grossMargins§0.73750997
ebitdaMargins§0.0
trailingPegRatio§None
